$10,000 invested in this ASX healthcare share a year ago is now worth $36,500

This stock has experienced a dramatic price increase.

ASX healthcare share Starpharma Holdings Ltd (ASX: SPL) has rocketed 365% over the past 12 months.

Had you put $10,000 into this ASX small-cap share in March 2025, your holdings would be worth $36,500 today.

Starpharma is an Australian biotech that develops drug delivery systems using proprietary polymers called dendrimers.

These nanoscale molecules make medicines more effective in the body.

Starpharma licenses its drug delivery technology to large pharma, and also develops its own anti-infection products.

This ASX healthcare share is trading at 47 cents on Thursday, up 1.1%.

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.

Image source: Getty Images

What's behind the dramatic 365% share price rise?

The bulk of Starpharma's rise over the past 12 months occurred between late September and February.

In September, the ASX healthcare share rose by more than 100% after the company announced two new partnerships.

Starpharma announced a new deal with drug company Genentech, which it has worked with for more than three years.

The companies will develop cancer treatments using Starpharma's proprietary DEP drug delivery technology.

Under the deal, Starpharma got an upfront payment of US$5.5 million.

It is also eligible to receive up to US$564 million in success-based payments over time.

Starpharma granted Genentech an exclusive global licence to commercialise any products developed via the collaboration.

Starpharma CEO Cheryl Maley said:

A key strategic priority for Starpharma is to build new, high-impact partnerships that unlock the full potential of our DEP platform.

By actively pursuing licensing opportunities and collaborating with leading organisations, we aim to expand market reach and enable our partners to deliver significantly improved therapies to patients worldwide.

The ASX healthcare share surged again when the company announced its first radiopharmaceutical partnership.

Starpharma signed a research and option agreement with Radiopharm Theranostics Ltd (ASX: RAD) that made it eligible to receive a $500,000 option fee, a $2 million upfront payment, and up to $89 million in success-based payments and royalties on net sales.

Maley called the deal a key milestone, and said radiopharmaceuticals was a strong area of focus for Starpharma.

In its 1H FY26 report in February, Starpharma reported a 474% increase in revenue to $10.8 million for the six months to 31 December.

The half-year profit was $1,367,000, up from a loss of $5,392,000 in 1H FY24.

Is it too late to buy this rising ASX healthcare share?

ASX biotech shares are notoriously risky and unsuitable for investors with a low risk tolerance.

PAC Partners gives this one a buy rating with a "high risk" 12-month price target of 80 cents to $1.

PAC Partners forecasts growth in partnerships as well as over-the-counter revenue over the next four years.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »